The main conventional drug classes for the treatment of hyperglycemia include: (1) sulfonylureas (improving the release of insulin from the pancreatic β cells); (2) biguanides and thiazolidinediones (TZDs) (lowering hepatic glucose production); (3) peroxisome proliferator-activated receptor-γ (PPARγ) agonists (stimulating the insulin activity); (4) sodium-glucose transport protein 2 (SGLT2) inhibitors (reducing glucose reabsorption); and (5) α-glucosidase inhibitors (interfering with absorption of glucose in the GI tract) [9]. Here, SLC5A2 is linked to Hyperglycemia.